![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Johns Hopkins University |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000201 |
The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders |
Drug: Selegiline |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Pharmacological Modulation of Cocaine Effects |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Maryland | |
Johns Hopkins University (BPRU) Bayview Campus | |
Baltimore, Maryland, United States, 21224 6823 |
Principal Investigator: | George Bigelow, Ph.D. | Johns Hopkins University |
Study ID Numbers: | NIDA-05196-1, R01-05196-1 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000201 |
Health Authority: | United States: Federal Government |
Cocaine-Related Disorders Selegiline Mental Disorders |
Substance-Related Disorders Disorders of Environmental Origin Cocaine |
Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Monoamine Oxidase Inhibitors Antiparkinson Agents |
Enzyme Inhibitors Central Nervous System Agents Protective Agents Neuroprotective Agents Pharmacologic Actions |